A research group led by Prof. WANG Hui from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences has introduced a metal-free nanozyme based on graphene quantum dots (GQDs) for highly efficient tumor chemo dynamic therapy (CDT).
The study was published in Matter.
GQDs represent a promising and cost-effective means of addressing the toxicity concerns associated with metal-based nanozymes in tumor CDT. However, the limited catalytic activity of GQDs has posed significant challenges for their clinical application, particularly under challenging catalytic conditions.
Graphene quantum dots, emerging as a safer and more effective alternative to traditional metal-based nanozymes, address significant toxicity concerns in tumor CDT. However, until now, their clinical application has been limited due to their relatively low catalytic activity under challenging conditions. This has been a significant hurdle in leveraging their full potential in cancer treatment.
“The new GQDs, which are made from red blood cell membranes, are highly effective in treating tumors with few side effects,” said LIU Hongji, a member of the research team. “One of the advantages is that they are metal-free. In addition, they function as excellent peroxidase-like biocatalysts.”
To enhance the catalytic performance of the GQD-based nanocatalytic adjuvant, the researchers rationally designed GQDs using a diatomic doping strategy. The synergistic electron effect of introducing nitrogen and phosphorus into GQDs can generate highly localized states near the Fermi level, thus enabling efficient enzymatic activity compared to single heteroatom doping.
The obtained GQDs, derived from erythrocyte membranes, have been shown to possess impressive peroxidase-mimicking activity. As a result, the GQDs are highly effective at inducing apoptosis and ferroptosis of cancer cells in vitro. They also selectively target tumors, with a tumor inhibition rate as high as 77.71% for intravenous injection and 93.22% for intertumoral injection, with no off-target side effects.
This drug-free, target-specific, and biologically benign nanozyme has great potential as a potent biocatalyst for use in safe cancer treatment.
Schematic illustration showing the role of GQDs, derived from erythrocyte membranes, as peroxidase–mimic enzyme for tumor catalytic therapy. (Image by LIU Hongji)
Copyright © 2024 Hefei Institutes of Physical Science, CAS All Rights Reserved